Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 17
Figure 5. Europe Small Molecule API Market, 2017-2027, $ mn 20
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of Europe Small Molecule API Market 25
Figure 8. Primary Restraints and Impact Factors of Europe Small Molecule API Market 28
Figure 9. Investment Opportunity Analysis 32
Figure 10. Porter’s Fiver Forces Analysis of Europe Small Molecule API Market 35
Figure 11. Breakdown of Europe Small Molecule API Market by Source, 2020-2027, % of Revenue 39
Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Source, Value ($ mn) and Share (%) 40
Figure 13. Europe Small Molecule API Market: Synthetic API, 2017-2027, $ mn 41
Figure 14. Europe Small Molecule API Market: Branded Synthetic API, 2017-2027, $ mn 42
Figure 15. Europe Small Molecule API Market: Generic Synthetic API, 2017-2027, $ mn 43
Figure 16. Europe Small Molecule API Market: Semi-synthetic API, 2017-2027, $ mn 44
Figure 17. Europe Small Molecule API Market: Natural Origin, 2017-2027, $ mn 45
Figure 18. Breakdown of Europe Small Molecule API Market by Type, 2020-2027, % of Revenue 46
Figure 19. Contribution to Europe 2021-2027 Cumulative Revenue by Type, Value ($ mn) and Share (%) 47
Figure 20. Europe Small Molecule API Market: Standard API, 2017-2027, $ mn 48
Figure 21. Europe Small Molecule API Market: High Potency API (HPAPI), 2017-2027, $ mn 49
Figure 22. Europe Small Molecule API Market: Branded HPAPI, 2017-2027, $ mn 50
Figure 23. Europe Small Molecule API Market: Generic HPAPI, 2017-2027, $ mn 51
Figure 24. Breakdown of Europe Small Molecule API Market by Therapeutic Area, 2020-2027, % of Revenue 53
Figure 25. Contribution to Europe 2021-2027 Cumulative Revenue by Therapeutic Area, Value ($ mn) and Share (%) 53
Figure 26. Europe Small Molecule API Market: Infectious Diseases, 2017-2027, $ mn 54
Figure 27. Europe Small Molecule API Market: Oncology, 2017-2027, $ mn 55
Figure 28. Europe Small Molecule API Market: Ophthalmology , 2017-2027, $ mn 56
Figure 29. Europe Small Molecule API Market: Cardiovascular Disorders, 2017-2027, $ mn 57
Figure 30. Europe Small Molecule API Market: Central Nervous System, 2017-2027, $ mn 58
Figure 31. Europe Small Molecule API Market: Respiratory Disorders, 2017-2027, $ mn 59
Figure 32. Europe Small Molecule API Market: Metabolic Diseases, 2017-2027, $ mn 60
Figure 33. Europe Small Molecule API Market: Other Applications, 2017-2027, $ mn 61
Figure 34. Breakdown of Europe Small Molecule API Market by Application, 2020-2027, % of Revenue 62
Figure 35. Contribution to Europe 2021-2027 Cumulative Revenue by Application, Value ($ mn) and Share (%) 63
Figure 36. Europe Small Molecule API Market: Clinical Use, 2017-2027, $ mn 64
Figure 37. Europe Small Molecule API Market: Commercial Use, 2017-2027, $ mn 65
Figure 38. Breakdown of Europe Small Molecule API Market by Manufacturer Type, 2020-2027, % of Revenue 66
Figure 39. Contribution to Europe 2021-2027 Cumulative Revenue by Manufacturer Type, Value ($ mn) and Share (%) 67
Figure 40. Europe Small Molecule API Market: Pharmaceutical Companies, 2017-2027, $ mn 68
Figure 41. Breakdown of Europe Small Molecule API In-house Synthesis Market by Region, 2020-2027, % of Revenue 69
Figure 42. Europe Small Molecule API Market: CMOs, 2017-2027, $ mn 70
Figure 43. Breakdown of Europe Small Molecule API Contract Synthesis Market by Region, 2020-2027, % of Revenue 71
Figure 44. Breakdown of European Small Molecule API Market by Country, 2020 and 2027, % of Revenue 73
Figure 45. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 74
Figure 46. Small Molecule API Market in UK, 2017-2027, $ mn 75
Figure 47. Small Molecule API Market in France, 2017-2027, $ mn 77
Figure 48. Small Molecule API Market in Germany, 2017-2027, $ mn 79
Figure 49. Small Molecule API Market in Spain, 2017-2027, $ mn 81
Figure 50. Small Molecule API Market in Italy, 2017-2027, $ mn 83
Figure 51. Small Molecule API Market in Russia, 2017-2027, $ mn 85
Figure 52. Small Molecule API Market in Rest of Europe, 2017-2027, $ mn 87
Figure 53. Growth Stage of Europe Small Molecule API Industry over the Forecast Period 89
Europe small molecule active pharmaceutical ingredient (API) market accounted for $38.35 billion in 2020 and will grow by 7.7% annually over 2020-2027 owing to increasing incidences of diseases, development of companies engaged in the manufacturing of small molecule APIs, the increasing technological developments in manufacturing sector, and surge in healthcare expenditure amid COVID-19 pandemic. Highlighted with 36 tables and 53 figures, this 113-page report “Europe Small Molecule API Market 2020-2027 by Source (Synthetic, Semi-synthetic, Natural), Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe small molecule API market in every aspect of the classification from perspectives of Source, Type, Therapeutic Area, Application, Manufacturer Type, and Country. Based on Source, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Synthetic API o Branded Synthetic API o Generic Synthetic API • Semi-synthetic API • Natural Origin Based on Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Standard API • High Potency API (HPAPI) o Branded HPAPI o Generic HPAPI Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Applications Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. o Clinical Use o Commercial Use Based on Manufacturer Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2017-2027 included in each section. • Pharmaceutical Companies • CMOs Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2017-2027. The breakdown of key national markets by Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Aurobindo Pharma Ltd. Cambrex Corporation Catalent, Inc. Dr. Reddy's Laboratories Ltd. GlaxoSmithKline plc Lonza Group Merck & Co., Inc. Mylan N.V. Novartis AG Pfizer Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Wuxi AppTec Co., Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More